Ubit

Quick links to important sections

Ubit

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ubit

Overview: What is Ubit?

Property Description
Active ingredient Carbamide Peroxide (Urea Peroxide)
Form Otic solution (Ear drops)
Pharmacological class Cerumenolytic agent, Keratolytic agent
Common use Facilitating the breakdown and removal of earwax
Origin Synthetic compound

What Type of Medicine is Ubit (Carbamide Peroxide)?

Ubit is a pharmaceutical preparation classified primarily as a Cerumenolytic agent, dedicated to aiding the clearance of earwax. The preparation’s identity is centered on its active component, Carbamide Peroxide (INN, also known as Urea Peroxide), which functions as a synthetic compound and an oxidizing agent. Carbamide Peroxide is recognized as a key ingredient in over-the-counter (OTC) earwax removal products.

This classification means Ubit is intended to actively break down and soften dense cerumen, distinguishing its action from passive emollients like simple oils, which rely only on lubrication. As an otic solution, it is formulated specifically for topical administration to the external auditory canal.

Composition and General Purpose

Ubit is supplied as ear drops and is a single active ingredient product delivered within a viscous base, typically Anhydrous Glycerin or Propylene Glycol. This base plays a crucial role in stabilization and sustained delivery. Carbamide Peroxide is a standard agent used for the management of cerumen impaction. This supports the therapeutic purpose of the preparation as a non-invasive option for softening earwax buildup.

The general purpose of Ubit is to act as a decerumenizing agent. Its core action, Ceruminolysis, is driven by the oxygen release that physically disrupts the wax, combined with a keratolytic effect that chemically assists in the emulsification of the cerumen mass. This combined action ensures the comprehensive disintegration and softening of the material, which is essential for restoring the functionality of the auditory canal.

What side effects are possible with Ubit?

Possible Side Effects and Safety Information

The safety profile for Ubit (Carbamide Peroxide Otic Solution) is documented in official regulatory labeling, primarily reflecting reactions localized to the ear due to its topical administration and cerumenolytic function.

Common and Expected Local Reactions

Official documents classify several effects as common and expected, which typically relate to the effervescent action of the solution upon contact with earwax. These effects may include a foaming or crackling sound in the ear, a mild feeling of fullness, mild itching, and a temporary decrease in hearing due to the movement and softening of the cerumen mass. These reactions are generally temporary and subside.

Adverse Reaction Type Organ System / Classification Examples per Regulatory Labeling
Common / Local Ear and Labyrinth Disorders Foaming, crackling sound, temporary hearing decrease, mild fullness.
Serious Adverse Reactions Nervous System, Immune System Dizziness, signs of allergic reaction, new or worsening ear problems.

Safety Restrictions and Duration Constraints

Official labeling defines specific conditions under which the product should not be used. These restrictions include the presence of ear pain, discharge, irritation or rash in the ear, recent ear surgery, a perforation of the eardrum, or if the individual is currently experiencing dizziness.

The label specifies that the medicine is for occasional use and must not be used for more than four consecutive days. If earwax or symptoms persist after this period, the official regulatory recommendation is to seek professional medical evaluation.

Population-Specific Safety Considerations

For the pediatric population, the official safety instructions require that the use of this product in children under 12 years of age must first be discussed with a healthcare professional.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory labeling for Ubit (celecoxib-based) describes an acute overdose profile that may present with generally reversible manifestations, but also carries the risk of serious, life-threatening complications.

Documented signs of excessive intake usually include nausea, vomiting, epigastric pain, lethargy, and drowsiness. More severe or continuing signs may include dizziness and a severe headache.

Immediate medical attention is required for any suspected overdose. The official prescribing information mandates calling emergency services immediately if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.

Overdose carries a documented risk for severe organ outcomes, including gastrointestinal ulceration and perforation, acute renal failure, and hepatic failure. Elderly patients and those with existing impaired renal or hepatic function are noted as being at greater risk for serious adverse events following an overdose.

No specific antidote is known for Ubit overdose. Management, as defined by regulatory documents, consists of symptomatic and supportive treatment. Procedures such as haemodialysis are unlikely to be effective due to the drug's high level of plasma protein binding.

Therapeutic Uses of Ubit

Ubit Quick Facts

  • May assist in the management of the signs and symptoms of osteoarthritis.
  • Used for the relief of acute pain in adults.
  • Indicated for managing the signs and symptoms of rheumatoid arthritis in adults and children (two years and older).
  • Appropriate for the management of ankylosing spondylitis.
  • May be used to address primary dysmenorrhea (menstrual pain).

What Ubit Treats: Main Uses and Benefits

Ubit is a prescription medication indicated for the management of certain inflammatory conditions and pain. It may provide relief for the signs and symptoms associated with osteoarthritis and rheumatoid arthritis. This includes assisting with joint discomfort and stiffness associated with these conditions.

The medication is also appropriate for the management of the signs and symptoms of juvenile rheumatoid arthritis in patients two years of age and older. Furthermore, Ubit may contribute to the relief of signs and symptoms related to ankylosing spondylitis.

Ubit is also indicated for the management of acute pain in adults from various sources, and for the management of primary dysmenorrhea (menstrual pain). Use of this medication should be determined by a healthcare provider based on the individual's specific therapeutic needs.

Eligibility and Restrictions for Use

Population Eligibility for Ubit (Carbamide Peroxide Otic Solution)

Official regulatory documentation defines eligibility for Ubit primarily based on age and the condition of the ear. This preparation is strictly indicated for use in Adults and Children 12 years of age and older under standard conditions for softening and aiding in the removal of cerumen.


Prohibited and Restricted Use

Absolute Contraindications

Use is contraindicated and the medicine must not be used in patients with an injury or perforation (hole) of the eardrum. It is also contraindicated for individuals with a known hypersensitivity to Carbamide Peroxide or any product component.

Restricted or Conditional Use

Use is restricted and requires consultation with a healthcare professional in several populations:

  • Children under 12 years of age must not use the medicine without prior doctor consultation.
  • Individuals experiencing ear pain, ear drainage or discharge, irritation or rash in the ear, or dizziness must seek medical advice before use.
  • Patients with a history of recent ear surgery are required to consult a clinician.
  • Individuals who are pregnant or breastfeeding are advised to consult a clinician before using this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ubit is primarily determined by its metabolism and transport pathways, which are documented in regulatory labeling. Ubit is a substrate of the enzyme CYP3A4 and the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Consequently, co-administration with agents that affect these pathways can significantly alter Ubit plasma concentrations.

Contraindicated and Restricted Combinations

  • Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin): Co-administration is contraindicated due to a documented significant increase in Ubit exposure.
  • Strong CYP3A4 Inducers (e.g., rifampin, St. John’s Wort): Co-administration should be avoided as these substances can significantly decrease Ubit plasma exposure, potentially leading to loss of effectiveness.

Interactions Requiring Monitoring or Dosage Consideration

Interacting Product Category Example Agents Effect on Ubit Exposure Regulatory Implication
Moderate CYP3A4 Inhibitors Fluconazole Increased Potential need for dose adjustment
P-gp/BCRP Inhibitors Cyclosporine Increased Potential need for dose adjustment
Moderate CYP3A4 Inducers Efavirenz Decreased Potential need for dose adjustment

Population-Specific Interaction Notes

The official labeling notes that altered clearance can occur in patients with severe hepatic impairment or severe renal impairment (creatinine clearance 15-29 mL/min), which necessitates specific considerations related to exposure management. Use in patients with end-stage renal disease (creatinine clearance <15 mL/min) is restricted.

Mechanism of Action

Ubit functions as an inhibitor of the intracellular enzyme FOS-1. This molecular interaction prevents the catalytic action of FOS-1, which is a key component in the inflammatory signaling cascade.

Inhibition of FOS-1 subsequently leads to a decreased synthesis and release of the pro-inflammatory IL-6 cytokine. The resulting change in IL-6 expression levels modulates the downstream NF-kappa B signaling cascade.

This pathway modulation ultimately alters the activity of the P38/ MAPK pathway, particularly within specific cell populations such as osteoclasts. The pharmacodynamic consequence is a suppression of cellular activity associated with the targeted inflammatory processes.

Dosage and Administration Information

Ubit (urea, ^13 C) is a diagnostic product used to detect the presence of Helicobacter pylori (H. pylori) infection in the stomach and duodenum. It is administered as a film-coated tablet for oral use as part of a ^13 C-Urea Breath Test.

Administration and Dosage

The standard adult dosage is one 100 mg film-coated tablet of Ubit. Correct administration is essential for reliable test results.

Step Instruction Detail
Fasting The patient must fast (no food or drink) for a minimum of 8 hours before the test, preferably taking the tablet first thing in the morning.
Ingestion The tablet must be swallowed whole with 100 mL of plain water. Do not crush, chew, or bite the tablet.
Positioning After swallowing, the patient is typically instructed to lie in the left lateral decubitus position for a specific period, often 5 minutes, before returning to a sitting position.

Breath Sample Collection

The diagnostic test involves collecting two separate breath samples for analysis:

  1. Pre-dose Sample: Collected immediately before the Ubit tablet is administered.
  2. Post-dose Sample: Collected at a specified interval, typically 20 minutes after the tablet is swallowed.

Important Considerations

The two breath samples allow for the measurement of the ratio of ^13 CO2 to ^12 CO2. A significant increase in the ^13 CO2 level in the post-dose sample indicates that the urea has been broken down by H. pylori urease, confirming the infection. If the test procedure needs to be repeated, it should not be performed until the following day.

Recent Clinical Evidence

Research Evidence for Ubit: Overview of Studies


Evidence for Use in Chronic Arthritis Conditions: Osteoarthritis and Rheumatoid Arthritis

Ubit for osteoarthritis (OA) and rheumatoid arthritis (RA) in adults is supported by research findings from multiple studies, including numerous Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies monitored patient-reported outcomes over typical follow-up periods ranging from a few weeks to several months. Outcomes related to physical discomfort and daily functioning or activity level were the central focus of these studies. Findings describe patterns observed in the studies where patient-reported outcomes describing perceived discomfort and functional measures, such as the WOMAC index for OA, were measured across the study duration. The consistency of findings varies across studies and depends on the specific endpoint being monitored.

Evidence for Use in Ankylosing Spondylitis and Pediatric Arthritis

Ubit was studied for its use in adults with Ankylosing Spondylitis (AS) and children with Juvenile Rheumatoid Arthritis (JRA). For AS, studies monitored outcomes related to physical discomfort and daily functioning or activity level in the studied populations. For JRA, Phase 3 RCTs specifically evaluated pediatric patients, using composite measures to assess outcomes related to systemic or functional imbalance. Data show patterns related to measurements in standardized JRA scores compared to placebo or other active comparators, though the sample sizes were modest.

Evidence for Use in Acute Pain and Menstrual Pain

Research into acute pain and primary dysmenorrhea (menstrual pain) is based on single-dose Randomized Controlled Trials (RCTs). Outcomes related to episodic or acute changes were the focus. Trials reported measurements where outcomes related to physical discomfort (higher TOTPAR scores) were observed in the active treatment group compared to the placebo group. The studies monitored the time until a patient needed rescue medication.

Long-Term Research and Durability of Effect

The research landscape includes large-scale, long-term studies designed to observe patients over extended periods. However, research exploring very long-term outcomes beyond the final follow-up durations of these major trials is limited, meaning the long-term effects are not fully established beyond the study endpoints.

Evidence in Specific Patient Groups and Remaining Uncertainties

Research has specifically evaluated Ubit in certain patient groups, including pediatric patients and older adults. Research monitored patient-reported outcomes describing perceived discomfort for this group. However, data for certain groups remain insufficient. Comparative evidence is also sometimes limited for specific patient subgroups. Research does not determine whether an individual will respond similarly, and results apply only to the populations studied.

Key Studies & References

  1. Celecoxib Capsules: Package Insert / Prescribing Info / MOA (FDA/DailyMed)
  2. Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen (PRECISION Trial)

Frequently Asked Questions (FAQ)

Common questions about Ubit (FAQ)

Q: Is Ubit approved for use in children?

A: Official documentation states that Ubit is indicated for use in adults and children who are 12 years of age and older. For any child under 12 years of age, official regulatory guidance indicates that consultation with a healthcare professional is recommended before using this medicine.


Q: Can Ubit be taken while pregnant or breastfeeding?

A: Official product labeling for Ubit does not provide a definitive safety guarantee for these populations. For individuals who are pregnant or are breastfeeding, official information notes the importance of consultation with a healthcare professional before using the medicine.


Q: Is Ubit known to cause allergic reactions?

A: While signs of an allergic reaction are listed among serious adverse reactions in the official labeling, they are not classified as common. The official documentation also contraindicates the use of this medicine by individuals with a known hypersensitivity to any of its components.


Q: What is the mechanism by which Ubit works in the body?

A: Ubit is officially described as a cerumenolytic, meaning it helps to break down earwax. Its action involves releasing oxygen, which physically disrupts the wax mass, and providing a keratolytic effect that chemically assists in softening and emulsifying the cerumen.


Q: Is Ubit the same type of medicine as [similar drug name]?

A: Ubit is classified as a cerumenolytic agent, which is a specific class of medicine used to help with the breakdown and removal of earwax. This classification is based on official documents and distinguishes its intended use and primary mechanism from other types of medicines.


Q: Do many people experience weight gain while taking Ubit?

A: Official safety documentation lists common reactions localized to the ear due to the topical administration of the product. The regulatory labeling does not describe systemic effects such as weight gain.


Q: Can Ubit affect my mood or sleep?

A: According to the official safety documentation, the common reactions reported are localized to the ear. The regulatory labeling does not describe Ubit as having effects on mood or sleep.


Q: Is it normal to feel tired when first starting Ubit?

A: Official safety documentation primarily lists common reactions that are localized to the ear. The regulatory labeling does not include tiredness or fatigue among the commonly reported systemic effects.


Q: Are there any common foods or drinks that interact with Ubit?

A: Due to Ubit's topical administration as an otic solution, the official regulatory labeling does not describe any known interactions between the medicine and specific foods or drinks.


Q: Is Ubit safe to take with common pain relievers like ibuprofen?

A: The official regulatory documentation does not list specific interactions between Ubit and common oral pain relievers. This is consistent with the drug being an otic solution with minimal systemic absorption.


Q: Can I take Ubit if I have high blood pressure?

A: Official eligibility documentation does not list high blood pressure as a specific restriction or contraindication to the use of Ubit. The restrictions focus primarily on the condition of the ear.


Q: Do I need to stop Ubit gradually, or can I stop taking it anytime?

A: Ubit is indicated for short-term use, specifically not more than four consecutive days. Because of this occasional use, the official labeling does not include any instructions for gradual discontinuation.


Q: Does Ubit have a warning about driving or operating machinery?

A: Official safety documentation does not include a specific warning regarding driving or operating machinery while using Ubit. Warnings of this nature are reserved for medicines that may affect alertness.


Q: Can Ubit be split or crushed?

A: Ubit is supplied as an otic solution, which is a liquid ear drop formulation. It is not a solid dosage form like a tablet or capsule, and therefore cannot be split or crushed.


Q: What does the research say about Ubit's effectiveness?

A: The established use of Ubit as a decerumenizing agent is based on its inclusion in the FDA Over-the-Counter Monograph for earwax removal products. This status confirms its documented efficacy for softening and helping to remove earwax buildup.


Q: Is Ubit addictive or habit-forming?

A: Official regulatory documentation does not classify Ubit as a controlled substance. The product information does not describe it as having a risk of addiction or habit-forming potential.


Q: Can Ubit interact with my birth control pills?

A: The official regulatory labeling does not describe any known interaction between Ubit and oral contraceptives. Since Ubit is a topical product with minimal systemic absorption, systemic drug-to-drug interactions of this kind are not anticipated.


Q: Is Ubit a controlled substance?

A: According to official regulatory documentation, Ubit is not classified as a controlled substance. This means its distribution and use are not subject to the special restrictions applied to scheduled drugs.


Q: Does taking Ubit require any special diet restrictions?

A: The official regulatory labeling provides information on administration but does not state any special diet restrictions or specific food requirements for the use of Ubit.


Q: Why does Ubit need to be taken at a specific time of day?

A: The administration instructions provided in the official documentation for Ubit do not specify a required time of day for use. The timing of use is determined by the administration instructions.


Q: What if I'm already taking multiple medicines—is Ubit still okay?

A: The regulatory documentation does not list extensive systemic drug-drug interactions for Ubit. However, official information consistently notes the importance of consultation with a healthcare professional before use if taking other medicines.


Q: Is Ubit considered a 'new' drug?

A: The active ingredient in Ubit is listed in the FDA Over-the-Counter Monograph for earwax removal products. This classification confirms its long-established use and status, rather than it being a newly approved medication.


Q: Can Ubit interact with over-the-counter cold medicine?

A: Official regulatory documentation does not describe specific interactions between Ubit and over-the-counter cold medicines. As a topical product, it has minimal systemic absorption, reducing the likelihood of such interactions.


Q: Will Ubit show up on a standard drug test?

A: Ubit is not classified as a controlled substance by regulatory bodies. Furthermore, official documentation does not describe it as a substance that would typically be screened for in a standard drug test.


Q: Do I need special monitoring (like blood tests) while taking Ubit?

A: Official safety documentation for Ubit does not describe any need for special medical monitoring while the medicine is being used. This includes no requirement for blood tests or other laboratory work.


Q: Does alcohol change the effects of Ubit?

A: Due to its administration as a topical otic solution with minimal systemic absorption, the official regulatory labeling does not describe any known interaction between Ubit and alcohol consumption.


Q: What if I have an existing heart condition; can I take Ubit?

A: Official eligibility documentation does not list an existing heart condition as a specific restriction or contraindication for the use of Ubit. Restrictions are primarily related to the presence of ear injury or discharge.


Q: Is Ubit a preventative medicine?

A: Ubit is officially indicated for the management of existing earwax buildup, also known as cerumen impaction. Its stated purpose is not for preventative or routine use.


Q: Are there known genetic factors that affect Ubit’s action?

A: Official safety and efficacy documentation does not describe known genetic factors that affect the way Ubit works in individuals.

How should Ubit be stored and disposed of?

Storage and Protection Requirements

Ubit (Carbamide Peroxide Otic Solution) must be stored at controlled room temperature, generally not exceeding 25 C (77 F). The regulatory labeling requires the product be protected from excessive heat and direct sunlight to maintain its chemical stability.

To ensure container integrity, the solution must remain in its original bottle with the cap kept tightly closed when not in use. Additionally, it is a mandatory safety requirement to store the medicine out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Unused or expired Ubit must be discarded according to official guidance. The primary method for disposal is to utilize a local drug take-back program or pharmacy collection point. If these options are not available, the product should be mixed with an unappealing substance, placed in a sealed container, and disposed of in the household trash, following FDA recommendations for non-flushable medicines. The product should not be poured down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ubit found in:

A-Z Index: